Infections after anti-BCMA CAR T-cell infusion. (A) Type of infectious microorganisms after anti-BCMA CAR T-cell infusion. (B) Infection sites after anti-BCMA CAR T-cell infusion. (C) Number of infections during different periods of time after CAR T-cell infusion. **P < .01, ***P < .001, compared with number of infections that occurred within 60 days after CAR T-cell therapy. (D) Serum IgG concentration during infection in patients with non-IgG MM with mild/moderate or severe/life-threatening infections. (E) Serum IgM concentration during infection in patients with non-IgM MM with mild/moderate or severe/life-threatening infections. (F) Serum IgA concentration during infection in patients with non-IgA MM with mild/moderate of severe/life-threatening infections. (D-F) Each point represents a single value from 1 person. Horizontal lines indicate median and interquartile range. The significance of the results were calculated by the Kruskal-Wallis test.